Prognostic impact of CD30 expression in COO subtypes of DLBCL. (A-B) OS (A) and PFS (B) of patients with CD30⁺ DLBCL of the GCB subtype in the training set. (C) OS of patients with CD30⁺ DLBCL of the GCB subtype in the combined training and validation sets. (D-E) OS (D) and PFS (E) of patients with CD30⁺ DLBCL of the ABC subtype in the training set. (F) OS of patients with CD30⁺ DLBCL of the ABC subtype in the combined training and validation sets.